CD274 and squamous cell carcinoma: Subgroup analysis based on histopathological type indicated that chemotherapy combined with ICIs, whatever atezolizumab or pembrolizumab, showed similar benefits in terms of mOS and mPFS between nonsquamous and squamous cell carcinoma in PD‐L1 unselected patients.